A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies
Kyaw L. Aung,Philippe L. Bedard,Philippe L. Bedard,Celeste Yu,Scott Boerner,Philip C. Zuzarte,Sangeet Ghai,Hal K. Berman,Stefano Serra,Amanda Giesler,Lailah Ahmed,Anthony M. Joshua,Malcolm J. Moore,Amit M. Oza,Amit M. Oza,Eitan Amir,Eitan Amir,John Douglas Mcpherson,Tong Zhang,Mahadeo A. Sukhai,Tracy Stockley,Tracy Stockley,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Lillian L. Siu,Lillian L. Siu,Aaron R. Hansen,Aaron R. Hansen +27 more
TL;DR: Optimally processed FNB and liquid biopsy can be used routinely for tumor mutation profiling to identify actionable mutations.
Journal ArticleDOI
Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.
Amit M. Oza,Stephanie Lheureux,Ainhoa Madariaga,Mihaela C. Cristea,Gina Mantia-Smaldone,Alexander B. Olawaiye,Susan Ellard,Johanne I Weberpals,Andrea E. Wahner Hendrickson,Gini F. Fleming,Stephen Welch,Neesha C. Dhani,Vanessa Speers,Valerie Bowering,Lisa Wang,Wenjiang Zhang,Eric Chen +16 more
TL;DR: The results indicate that the current adavosertib dosing regimen may not produce the desired concentrations in tumors for some patients, and further optimization may be needed.
Proceedings ArticleDOI
2022-RA-678-ESGO CONTESSA/NEOCON-F trial: Assessing the effectiveness and safety of neoadjuvant chemotherapy followed by fertility-sparing surgery in FIGO 2018 stage IB2 cervical cancer
Marie Plante,Nienke E. van Trommel,Mirte Schaafsma,Amit M. Oza,Angela Rodriguez,Lisa Wang,Karolina Sikorska,Sarah E. Ferguson,Kathy Han,Stephanie Lheureux,Frédéric Amant +10 more
TL;DR: The ContESSA/NEOCON-F trial as discussed by the authors evaluated a promising fertility-saving treatment: neoadjuvant chemotherapy (NACT) followed by fertility-sparing surgery (FSS).
Journal ArticleDOI
An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer
TL;DR: In this article , a second course of olaparibib can be safely administered to women with BRCA-mutated epithelial ovarian cancer (EOC) by using PARP inhibitors.
Journal ArticleDOI
An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian cancer.
TL;DR: In this paper , a second course of olaparibib can be safely administered to women with BRCA mutated epithelial ovarian cancer (EOC) and showed that the second course is safe.